Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kiora Pharmaceuticals, Inc. (KPRX : NSDQ)

• Company Description    Kiora Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company. It involved in developing and commercializing products for treating ophthalmic diseases. The company's product pipeline includes KIO-301, KIO-101 and KIO-201. Kiora Pharmaceuticals Inc., formerly known as EyeGate Pharmaceuticals Inc., is based in SALT LAKE CITY. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $1.97 Daily Weekly Monthly 20 Day Moving Average: 24,312 shares Shares Outstanding: 3.68 (millions) Market Capitalization: $7.25 (millions) Beta: -0.89 52 Week High: $4.18 52 Week Low: $1.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.37% -8.22% 12 Week -30.14% -31.27% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 169 SAXONY RD. SUITE 212 - ENCINITAS,CA 92024 USA ph: 858-224-9600 fax: - investors@kiorapharma.com http://www.kiorapharma.com

• General Corporate Information    Officers Brian M. Strem - President and Chief Executive Officer Melissa Tosca - Chief Financial Officer Praveen Tyle - Director Lisa Walters-Hoffert - Director David Hollander - Director Peer Information Kiora Pharmaceuticals, Inc. (GSAC) Kiora Pharmaceuticals, Inc. (CASI) Kiora Pharmaceuticals, Inc. (ALCD.) Kiora Pharmaceuticals, Inc. (OMNN) Kiora Pharmaceuticals, Inc. (CGPI.) Kiora Pharmaceuticals, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 49721T507 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/24/26 Share - Related Items Shares Outstanding: 3.68 Most Recent Split Date: 6.00 (0.11:1) Beta: -0.89 Market Capitalization: $7.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/24/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.30 Price/Cash Flow: 1.59 Price / Sales: - EPS Growth vs. Year Ago Period: 101.23% vs. Previous Quarter: 101.85% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -36.35 06/30/25 - -47.17 ROA 12/31/25 - - 09/30/25 - -25.82 06/30/25 - -34.00 Current Ratio 12/31/25 - - 09/30/25 - 8.80 06/30/25 - 7.76 Quick Ratio 12/31/25 - - 09/30/25 - 8.80 06/30/25 - 7.76 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 6.53 06/30/25 - 7.27 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©